Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2013. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility (PDMR), or connected persons, specifically regarding the vesting of conditional share awards.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification regarding equity compensation and does not contain financial statements or performance metrics.
Material Changes
The material event reported is the lapse of a conditional share award due to the non-achievement of a relevant business performance condition. The three-year performance period for the award ran from January 1, 2010, to December 31, 2012.
Management Commentary and Unusual Items
- Share Award Lapse: The Remuneration Committee confirmed that an award made in 2010 under the GlaxoSmithKline 2009 Performance Share Plan lapsed in full on March 5, 2013.
- Parties Involved: The award was held by Mrs. K Thomson, a connected person of Mr. P Thomson (a PDMR).
- Impact: A total of 178 Ordinary Shares lapsed as a result of the unmet performance condition.
Investor Verification Checklist
- Verify the specific business performance conditions attached to the 2009 Performance Share Plan that were not met.
- Confirm the total number of shares lapsed across all PDMRs and connected persons for the 2010 award cycle.
- Review the company's broader 2012 annual report for context on overall performance metrics that influenced this specific award outcome.